Duchenne muscular dystrophy (DMD) is one of the most common and devastating types of muscular degeneration and results in progressive muscle weakness starting at an early age1,2
DMD is a genetic, degenerative disease that is inherited in an X-linked recessive mode with an incidence of up to 1 in 3,500 live born males worldwide.1–4 The average age of symptoms onset is between 3 and 5 years, with patients experiencing progressive weakness of muscles, usually leading to the loss of ambulation as teenagers.1,3,5
DMD is characterized by a loss of the protein dystrophin, leading to cell damage, impaired calcium homeostasis, elevated oxidative stress and reduced energy production in muscle cells.3,4 This results in progressive muscle weakness, loss of muscle tissue and early morbidity and mortality due to cardio-respiratory failure.2–4, 6–13 Progressive respiratory muscle weakness leads to restrictive respiratory disease, hypoventilation, ineffective cough, recurrent pulmonary infections, atelectasis, respiratory failure and ultimately the need for daytime ventilation.14–16 As respiratory insufficiency develops, mechanical ventilation becomes necessary to prolong survival beyond the late-teenage years.2,6,13,17
New treatments are urgently needed to slow disease progression in patients with DMD
Currently, glucocorticoids are the only available medical treatment that can slow the decline in muscle strength and function, irrespective of the disease-causing mutation.3,5,13,17,18 However, the effect is only partial and clinical use is limited by well-known side effects caused by steroids.3,5,13,17,18 A recent study showed that up to 42% of DMD patients aged 10 years and older had either never used steroids or have discontinued their use.5 Loss of respiratory function with increasing age continues to be a major cause of morbidity and mortality in patients with DMD, and new treatments to support respiratory function are needed urgently.2,6,13,17
Santhera has partnered with Parent Project Muscular Dystrophy (PPMD) to study patient and caregiver preferences regarding the benefits and risks of pulmonary therapies in DMD.19
Santhera’s clinical development program with idebenone in DMD started with a Phase 2 randomized, placebo-controlled trial (the DELPHI trial).20,21
The DELOS trial evaluated the efficacy and safety of idebenone in delaying the loss of respiratory function in patients with DMD compared with placebo.5 DELOS was a double-blind, randomized, placebo-controlled Phase 3 study in patients with DMD aged between 10 and 18 years who were not using concomitant corticosteroids.6 The results of the DELOS trial have been published in several peer-reviewed journals.6,22,23,24,25
The SIDEROS study is a double-blind, randomized, placebo-controlled Phase 3 clinical trial evaluating the efficacy of idebenone compared to placebo in delaying the loss of respiratory function in patients with DMD receiving glucocorticoid steroids. More on SIDEROS can be viewed at www.siderosDMD.com. For additional information regarding this ongoing trial, please email firstname.lastname@example.org.
Puldysa has been granted Orphan Drug status in the US and in Europe, Fast Track and Rare Pediatric Disease designations by the US FDA and Promising Innovative Medicine (PIM) status by the UK MHRA. In the UK, Puldysa is available to patients through the Early Access to Medicines Scheme (EAMS).
Santhera launched the "Take a Breath DMD" campaign to underscore the importance of respiratory care for people living with DMD. The mission of this educational campaign is to help people living with DMD and their families receive information to help manage respiratory complications, including information about breathing, coughing and pulmonary care.
If you are residing in the US and are interested in learning more about respiratory function in DMD please visit www.takeabreathdmd.com.
Interested parties outside the USA visit www.breatheduchenne.com.
Santhera provides access to the investigational medicine idebenone for eligible patients 8 years of age and older with DMD through a U.S. Expanded Access Program (EAP) referred to as BreatheDMD. EAPs such as BreatheDMD are permitted by the U.S. Food and Drug Administration (FDA). Such programs allow eligible patients with serious or life-threatening diseases or conditions, where there is a lack of satisfactory therapeutic alternatives, to gain access to a medicine under investigation before it is approved by regulatory authorities. Idebenone is a medicine that is under investigation for the treatment of DMD. It has not yet been approved by the U.S. FDA and the safety and efficacy continue to be evaluated in clinical trials. Details regarding this EAP, including eligibility requirements, can be obtained by visiting the website www.breatheDMD.com.
Mendell JR & Lloyd-Puryear M. Muscle Nerve 2013; 48:21–26.
Passamano L, et al. Acta Myol 2012; 31:121–125.
Bushby K, et al. Lancet Neurol 2010; 9:77–93.
Timpani CA, et al. Med Hypotheses 2015 ; 85:1021–1033.
Henricson EK, et al. Muscle Nerve 2013; 48:55–67.
Buyse GM et al. The Lancet 2015; 385:1748–1757.
Inkley SR, et al. Am J Med 1974; 56:297–306.
Rideau RY, et al. Muscle Nerve 1981; 4:155–164.
McDonald CM, et al. Am J Phys Med Rehabil 1995; 74:S70–S92.
Tangsrud S, et al. Resp Med 2001; 95:898–903.
Kohler M, et al. Am J Respir Crit Care Med 2005; 172:1032–1036.
Bushby K, et al. Lancet Neurol 2010; 9:177–189.
Buyse GM, et al. Eur Neurol Rev 2015; 10:189–194.
Melacini P, et al. Neuromuscul Disord 1996; 6:367–376.
Simonds AK. Semin Respir Crit Care Med 2002; 23:231–238.
Bourke SC. Clin Med 2014; 14:72–75.
LoMauro A, et al. Ther Clin Risk Manag 2015; 11:1475–1488.
Ricotti V, et al. J Neurol Neurosurg Psychiatry 2013; 84:698–705.
Hollin et al., Muscle & Nerve 2017; 55:626-634.
Buyse GM, et al. Neuromuscul Disord 2011; 21:396–405.
Buyse GM, et al. Pediatr Pulmonol 2013; 48:912–920.
McDonald et al. Neuromuscul Disord 2016; 26:473-480.
Buyse et al., Pediatr Pulmonol 2017; 52:580-515.
Mayer et al., J Neuromuscul Dis 2017; 4:189-198.
Meier et al., Neuromuscul Disord 2017; 27:307-314.